Treatment of advanced lung cancer based on genomic profiling using liquid biopsy (plasma): A review of three cases

Abstract

Abstract Of the 80 solid tumor cases in which liquid biopsy (LB) was performed using Guardant360 in the PROFILE study, nine were lung cancer cases. Here, we review three cases in which LB was useful in diagnosing ALK fusion‐positive lung cancer, selecting sequential ALK‐tyrosine kinase inhibitors, confirming uncommon EGFR mutations, and receiving biomarker‐compatible therapy.

Keywords

• gene profiling
• liquid biopsy
• lung cancer